Filing summary
Entity and period: The supplied filing is Venaxis, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2016—not a Riot Platforms, Inc. filing. Investors should verify the issuer before relying on this summary.
Business context and financial results
Venaxis was winding down APPY 1 commercial activities in Europe and reducing operations while assessing strategic alternatives for its appendicitis assets. It reported no product sales in Q1 2016, compared with $11,288 in Q1 2015. License-fee revenue was $24,175 in each period.
- Profit/loss: Net income was $559,511, versus a $2,186,373 net loss in Q1 2015. The 2016 profit primarily reflected a $1.919 million gain on the sale of the company headquarters; operating loss remained $1.379 million, compared with $2.212 million.
- Expenses: Operating expenses were $1.403 million, down from $2.244 million. SG&A fell to $1.030 million from $1.536 million; R&D fell to $373,000 from $708,000. Patent impairment charges were $134,000, versus none in Q1 2015.
- Margins: No product gross margin was reported in Q1 2016 because there were no product sales. The filing does not provide a meaningful overall margin comparison.
- Cash flow: Operating cash use was $1.903 million, compared with $2.287 million. Investing activities provided $3.849 million, including about $1.749 million of cash proceeds from the property sale; financing used $117,000 for debt repayments. Cash increased $1.829 million to $3.841 million.
- Liquidity: Cash, cash equivalents and short-term investments totaled approximately $16.6 million; working capital was $16.183 million. Total assets were $18.474 million and stockholders’ equity was $16.678 million at quarter-end.
- Debt and liabilities: Notes and other obligations were $57,152, all current, after the headquarters sale paid off the mortgage. Total liabilities were $1.796 million, including $1.235 million of deferred revenue.
- Per share: Reported basic and diluted earnings per share were $0.14, versus a loss per share of $0.56. A one-for-eight reverse stock split took effect March 31, 2016; historical share figures were retrospectively adjusted.
Material changes and notable events
- On February 25, 2016, Venaxis sold its headquarters and certain assets for approximately $4.053 million, recording a gain of about $1.9 million and generating approximately $1.7 million in net cash after costs and mortgage payoffs. It leased back space under short-term arrangements.
- The company began winding down APPY 1 sales and reduced its workforce, citing limited European sales and losses. It notified four European distributors that their agreements would be terminated; two disputed the termination.
- The proposed Strand combination transaction was terminated by mutual agreement on March 11, 2016. Each party remained responsible for its own transaction costs.
- Expenses declined partly because of the operating wind-down, staff reductions and lower stock compensation; strategic-evaluation costs increased by approximately $302,000.
Outlook, risks and contingencies
Management expected near-term operating losses, potentially significant, and estimated existing working capital would fund needs into early 2017. It was evaluating strategic alternatives, including partnering, licensing or monetizing the appendicitis portfolio, and continuing cost controls. The filing gives no specific earnings or revenue guidance. Management said additional financing might be pursued but was not assured.
- Approximately $374,000 of capitalized acute-appendicitis patent costs could be impaired if no strategic partner or other party is found to advance development or commercialization.
- The company reported recurring losses, negative operating cash flows and an accumulated deficit of approximately $105.0 million. Its financial statements contained no adjustments for possible future effects if it could not continue as a going concern.
- Two distributors disputed Venaxis’s right to end their agreements; the company considered the claims without merit and expected any resolution not to be material. The agreements provide for attempted management resolution followed by binding arbitration.
- Animal-health license agreements include potential milestone payments of up to $1.1 million, with up to an additional $2 million for further products, as well as royalties, contingent on milestones and sales.
- Management reported disclosure controls and procedures were effective as of March 31, 2016; it reported no material change in internal control during the quarter and no material change to previously disclosed risk factors.
Important facts for investors to verify
- Confirm that Venaxis, rather than Riot Platforms, is the intended issuer and that the 2016 Q1 period is correct.
- Assess cash burn and the basis for management’s estimate that liquidity would last into early 2017, including the impact of strategic costs and possible financing needs.
- Verify progress in finding a partner or other strategic path for the appendicitis assets and whether patent impairment charges may increase.
- Track the distributor dispute and any arbitration, settlement or related costs.
- Separate recurring operating performance from the one-time property-sale gain when assessing Q1 net income.